| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1265.4 | 1323.5 | 1119.7 |
| Other income | 4.9 | 8.1 | 8.6 |
| Total income | 1270.3 | 1331.6 | 1128.3 |
| Profit before exceptional items & tax | 137.7 | 153.0 | 130.3 |
| Exceptional items | 63.2 | -6.4 | -8.4 |
| Profit before tax | 199.6 | 148.1 | 122.0 |
| Net profit | 165.5 | 129.3 | 105.6 |
| Operating margin | 15.7% | 11.1% | 10.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +56.70% |
|---|---|
| Net profit, quarter on quarter | +28.00% |
| Revenue, year on year | +13.00% |
| Operating profit, year on year | +65.60% |
| Operating profit, quarter on quarter | +32.50% |
BSE results filing, NSE: STAR. Figures extracted from the filing.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,088.70
- Market cap
- ₹10,035 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.4×Sector 47.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Results Update
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
- Value
- ₹1,265 Cr